Are Allergy Shots Permanent? Durability Data After 3-5 Year Course
Allergy shots are not permanent in the absolute sense — no immunotherapy guarantees lifetime tolerance — but they are disease-modifying with durable remission lasting years to a decade-plus after a 3-to-5-year course. Durham SR et al. (NEJM 1999) showed 3-4 years of grass SCIT produced remission comparable to continued treatment for at least 3 further years. Relapse rates range 0%–55% depending on allergen type.
7 peer-reviewed sources
Allergy shots are not permanent but produce disease-modifying durable remission lasting 7-12+ years after a completed 3-to-5-year course — unlike antihistamines, which return symptoms immediately on stopping.
The essentials
Allergy shots are not permanent in the absolute sense — no allergen immunotherapy regimen guarantees lifetime tolerance for every patient. But "permanent" is the wrong frame: the operative clinical concept is "disease-modifying with multi-year durable remission," which is meaningfully closer to permanent than any pharmacotherapy can claim.
The landmark evidence is Durham SR, Walker SM, Varga EM et al. (NEJM 1999;341:468-475, DOI 10.1056/NEJM199908123410702): patients who completed 3–4 years of grass-pollen SCIT and then stopped maintained clinical remission comparable to continued treatment for at least 3 further years of follow-up, with persistent immunologic changes including sustained IgG4 elevation and reduced seasonal IgE rises. This was a randomized continuation-versus-discontinuation design — the strongest possible evidence for post-treatment durability.
Long-term observational data describe continued benefit 7–12+ years out. Walker SM et al. (JACI 2001;107:87-93, DOI 10.1067/mai.2001.112027) and Frew AJ et al. (JACI 2006 UK Immunotherapy Study) report sustained symptom reduction well beyond the standard treatment duration in patients who completed the full course.
Curex provides at-home IgE testing with board-certified allergist review so patients can match the right allergen profile to the immunotherapy regimen most likely to produce durable, multi-year remission.
The honest counterweight: Cox L and Cohn JR (Ann Allergy Asthma Immunol 2007, "Duration of allergen immunotherapy: when is enough, enough?") review relapse rates after SCIT discontinuation and find a wide range — 0%–55% — across allergens. Grass pollen has the lowest relapse rates (the Durham 1999 cohort is grass). Dust mite has the highest: relapse rates of up to 55% within 5 years of discontinuation have been reported. This is why the stop/continue decision after 3–5 years is individualized by allergen type and patient history.
Venom immunotherapy (VIT) is the closest thing to "permanent" in allergy medicine. Golden DBK et al. (JACI 2005) report VIT prevents systemic sting reactions in >95% of treated patients, and protection "often persists after stopping a 3-5 year course." The Cochrane VIT meta-analysis (Boyle RJ et al., Cochrane 2012, PMID 23076950) found subsequent systemic sting reaction in 2.7% of treated versus 39.8% of untreated patients (RR 0.10, 95% CI 0.03-0.28).
Pediatric durability: Jacobsen L et al. (Allergy 2007, PAT 10-year follow-up) showed that a 3-year pediatric pollen SCIT course roughly halved new-onset asthma at 10-year follow-up — a different permanence outcome (prevention of disease progression rather than sustained symptom remission).
Cost-effectiveness extends with durability: Cox L, Murphey A, Hankin C (Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122) found SCIT and SLIT become cost-effective versus standard drug therapy from approximately 6 years after initiation — meaning the longer the durability holds, the better the long-term economic case.
The truthful framing: allergy shots are disease-modifying with multi-year durable remission, especially for grass and ragweed pollen. The allergen-specific relapse risk and the individual patient's clinical response are the variables that determine whether the remission holds or whether re-treatment is warranted.
Curex's at-home allergy shot program (SCIT) at $129/month delivers the same disease-modifying mechanism — weekly subcutaneous allergen extract, personalized serum sterile-compounded to USP <797> standards, with board-certified allergist oversight — without the multi-year calendar of clinic visits. Eligible maintenance patients self-administer one weekly shot at home, with a prescribed epinephrine auto-injector confirmed on hand and first-dose Zoom supervision.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Disease-modifying durability of SCIT is best documented for pollen allergens. The Durham 1999 NEJM trial is the gold standard for demonstrating that benefit persists after stopping treatment.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
How long do allergy shots last after you stop?
The durability after stopping allergy shots depends on the allergen type and how many years of treatment were completed. The strongest evidence is Durham SR et al. (NEJM 1999;341:468-475): patients who completed 3-4 years of grass SCIT maintained clinical remission comparable to continued treatment for at least 3 further years — the study was not designed to detect remission beyond that follow-up window. Longer observational studies report continued benefit 7-12 years post-treatment for grass and ragweed. For dust mite, relapse can occur in up to 55% of patients within 5 years (Cox & Cohn, Ann Allergy Asthma Immunol 2007). Patients who stop before completing the standard 3-5 year course are less likely to achieve durable remission — completing the full course is the baseline requirement for maximizing post-treatment benefit.
Can allergies come back after finishing allergy shots?
Yes — allergies can return after completing allergy shots, but the probability depends on the allergen and how long the patient completed treatment. The relapse rate ranges from nearly 0% for some grass-pollen patients to up to 55% for dust-mite patients (Cox L, Cohn JR, Ann Allergy Asthma Immunol 2007). Relapse does not mean the treatment failed — it means the underlying immune sensitization re-emerges, which can be addressed by re-initiating a shorter consolidation SCIT course or switching to sublingual immunotherapy drops. Most allergists assess for relapse clinically: worsening seasonal symptoms, increased medication use, or return of positive skin test reactivity. Patients who relapse can typically be re-started on immunotherapy more quickly than a naive patient, since some immune memory persists.
Why are allergy shots called disease-modifying instead of curative?
"Disease-modifying" is the operative clinical term (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55) because SCIT changes the underlying immune response — reducing allergen-specific IgE, raising IgG4 blocking antibodies, expanding FOXP3+ regulatory T cells — rather than merely suppressing downstream symptoms. This is what makes SCIT different from antihistamines (which block histamine receptors symptomatically) or intranasal steroids (which suppress local inflammation). "Curative" is not used because relapse can occur after stopping treatment, meaning the underlying sensitization is not permanently extinguished in all patients. "Disease-modifying with durable remission" accurately captures what SCIT achieves: meaningful and often multi-year reduction in disease activity that outlasts the treatment period.
How do I know when to stop allergy shots?
The standard recommendation is to complete 3-5 years of maintenance therapy before considering discontinuation (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). The stop/continue decision after 5 years is individualized. Factors favoring discontinuation: stable symptom control for 2-3 consecutive allergy seasons, reduced medication use, positive patient preference. Factors favoring continuation beyond 5 years: dust-mite sensitization (higher relapse risk), severe baseline disease, history of prior treatment attempts, patient preference for continued protection. Some patients extend to 6-7 years. Venom immunotherapy continuation decisions follow a different protocol based on tryptase levels and sting-reaction history (Golden DBK et al., JACI 2005). The discussion should be individualized with the prescribing allergist.
Do allergy shots for children last longer than for adults?
Pediatric SCIT may provide a unique preventive durability that extends beyond symptom remission. The PAT (Preventive Allergy Treatment) study (Möller C et al., JACI 2002; Jacobsen L et al., Allergy 2007) showed that children who completed a 3-year grass/birch SCIT course had roughly half the rate of new-onset asthma at 10-year follow-up compared to untreated controls. This preventive effect on disease progression is a different durability endpoint than symptom remission. For symptom-level durability in children, the evidence is similar to adults — completing the full 3-5 year course provides multi-year post-treatment remission. Starting immunotherapy earlier in life (before extensive sensitization develops) may extend durability by modifying the disease trajectory rather than just treating established disease.
What happens if my allergies come back after allergy shots?
If symptoms return after completing and stopping a full SCIT course, re-initiation of immunotherapy is an option. Most allergists reassess with updated skin or blood testing to confirm current sensitization, then design a new course. Patients who have completed prior SCIT typically show faster immune response on re-treatment because some immune memory persists — this may allow a condensed build-up schedule, though this is allergist-determined. Alternatively, sublingual immunotherapy drops may be appropriate for patients who completed injections previously and prefer a home-based maintenance option. Relapse does not mean the original SCIT failed — it means the underlying sensitization has re-established over time, a recognized outcome for a subset of patients particularly sensitized to perennial allergens like dust mite.
Are allergy shots more permanent than sublingual allergy drops?
The durability evidence for both SCIT (injections) and SLIT (sublingual drops) shows similar patterns — multi-year post-treatment remission with allergen-dependent relapse risk. The Durham 1999 NEJM grass SCIT trial demonstrated 3+ year remission post-discontinuation. Equivalent durability data for sublingual drops is available: Didier A et al. (Allergy 2013) showed 3-year grass SLIT produced sustained benefit 2 years post-treatment. The mechanisms are the same — IgG4 induction, regulatory T-cell expansion, IgE reduction — and the immunological target is identical. Cox 2011 PP3 recognizes both routes as disease-modifying. Head-to-head durability trials comparing SCIT vs SLIT are limited, but current evidence does not support a conclusion that one route produces more permanent outcomes than the other.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAre Allergy Shots Better Than Pills? | Curex Guide
For moderate-to-severe allergies, yes: SCIT is disease-modifying (Cochrane SMD −0.73). Pills suppress symptoms only — stop the pill, symptoms return. Full comparison inside.
Read moreWhere To Get Allergy Shots | Curex Allergy Shot Guide
Get allergy shots at an allergist office or at home with Curex SCIT ($129/mo). HOPD sites can bill $24,400 for what a freestanding clinic charges $1,827.
Read moreAllergy Shot: SCIT Guide for Patients | Curex
An allergy shot is subcutaneous immunotherapy (SCIT) — a 3-to-5-year course. Cochrane 51 RCTs found SMD -0.73. Learn how it works, costs, and who qualifies.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreWhere To Give Allergy Shots | Curex Allergy Shot Guide
Give allergy shots SC in the upper outer arm (posterolateral deltoid), 26-27G ½-inch, alternating arms. At-home SCIT with Curex at $129/mo.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.